Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer

Alexander T Cohen, Theodore E Spiro, Paul Burton, Harry R Büller, Lloyd Haskell, Da-Yi Hu, Russell D Hull, Alexandre Mebazaa, Geno J Merli, Sebastian Schellong, Alex C Spyropoulos, Victor F Tapson

Blood (2011) 118 (21): 542.

https://doi.org/10.1182/blood.V118.21.542.542

Published: 2011

Journal Articles

Time Course of Venous Thromboembolism Events and Influence of Risk Factors in High Risk Medical Patients,

Russell D Hull, Tazmin Merali, BPharm, MBA, Allan Mills, PharmD, Jane Liang, Nelly Komari, BPharm, MSc

Blood (2011) 118 (21): 4182.

https://doi.org/10.1182/blood.V118.21.4182.4182

Published: 2011

Journal Articles

Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma

Jawed Fareed, PhD, Walter Jeske, Ph.D., Debra Hoppensteadt, Ph.D., Rakesh Wahi, MD, Russell D Hull

Blood (2011) 118 (21): 4328.

https://doi.org/10.1182/blood.V118.21.4328.4328

Published: 2011

Journal Articles

Rate and Time Course of Thromboembolism Events in Cancer Patients

Russell D Hull, Tazmin Merali, BPharm, MBA, Allan Mills, PharmD, Jane Liang, Nelly Komari, BPharm, MSc

Blood (2011) 118 (21): 4773.

https://doi.org/10.1182/blood.V118.21.4773.4773

Published: 2011

Journal Articles

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

Alexander GG Turpie, MD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Victor F Tapson, MD, Manuel Monreal, MD, Meyer Michel Samama, MD, PharmD, Roger D Yusen, MD, MPH

Blood (2008) 112 (11): 433.

https://doi.org/10.1182/blood.V112.11.433.433

Published: 2008

Journal Articles

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

Roger D Yusen, Russell D Hull, Sebastian M Schellong, Victor F Tapson, Manuel Monreal, Michel Meyer Samama, Min Chen, Alexander GG Turpie

Blood (2008) 112 (11): 438.

https://doi.org/10.1182/blood.V112.11.438.438

Published: 2008

Journal Articles

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

Frederick A Anderson, Jr., PhD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Bruno Deslandes, Victor F Tapson, MD, Meyer Michel Samama, MD, PharmD, Alexander GG Turpie, MD, Roger D Yusen, MD, MPH, Herve Decousus, MD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Manuel Monreal, MD

Blood (2008) 112 (11): 1981.

https://doi.org/10.1182/blood.V112.11.1981.1981

Published: 2008

Journal Articles

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Roger D. Yusen, Russell D. Hull, Sebastian M. Schellong, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie

Blood (2007) 110 (11): 1862.

https://doi.org/10.1182/blood.V110.11.1862.1862

Published: 2007

Journal Articles

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Victor F. Tapson, Russell D. Hull, Sebastian M. Schellong, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1863.

https://doi.org/10.1182/blood.V110.11.1863.1863

Published: 2007

Journal Articles

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Sebastian M. Schellong, Russell D. Hull, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1870.

https://doi.org/10.1182/blood.V110.11.1870.1870

Published: 2007

Journal Articles

Self-Managed Long-Term Low-Molecular-Weight Heparin Compared with Usual-Care Anticoagulation for Patients with Proximal Venous Thrombosis: Harm Associated with Bleeding!.

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F. Brant, PhD, for the LITE Trial Investigators

Blood (2005) 106 (11): 901.

https://doi.org/10.1182/blood.V106.11.901.901

Published: 2005

Journal Articles

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy Compared with Usual-Care Anticoagulation for the Treatment of Patients with Proximal Venous Thrombosis: Harm Associated with Thrombocytopenia.

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F. Brant, PhD, for the LITE Trial Investigators

Blood (2005) 106 (11): 4142.

https://doi.org/10.1182/blood.V106.11.4142.4142

Published: 2005

NARROW

The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer

Time Course of Venous Thromboembolism Events and Influence of Risk Factors in High Risk Medical Patients,

Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma

Rate and Time Course of Thromboembolism Events in Cancer Patients

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Self-Managed Long-Term Low-Molecular-Weight Heparin Compared with Usual-Care Anticoagulation for Patients with Proximal Venous Thrombosis: Harm Associated with Bleeding!.

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy Compared with Usual-Care Anticoagulation for the Treatment of Patients with Proximal Venous Thrombosis: Harm Associated with Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only